🩸 SGLT2 Inhibitor Mechanism Simulator

Normal Renal Glucose Handling — SGLT2 at the Proximal Tubule

Nearly all filtered glucose is reclaimed before urine forms.

• ~100%: Filtered glucose reabsorbed (below renal threshold)
• ~90%: SGLT2 share of reabsorption (S1/S2 tubule segment)
• ~180 mg/dL: Renal glucose threshold (spillover point)
• Proximal tubule apical membrane: Transporter location (brush border)

SGLT2 as the kidney glucose reclamation pump

Sodium-glucose cotransport pulls filtered glucose back into blood.

Why healthy kidneys excrete almost no glucose

Transport capacity comfortably exceeds normal filtered glucose load.

Empagliflozin & Dapagliflozin — Competitive SGLT2 Blockade

Gliflozin drugs occupy the transporter, stopping glucose capture.

• SGLT2 inhibitor (gliflozin): Drug class (oral, once daily)
• SGLT2 apical transporter: Binding site (competitive, reversible)
• Within hours: Onset of blockade (first dose effect)
• >1,000-fold: Selectivity vs SGLT1 (spares gut glucose uptake)

Selective competitive inhibition of the transporter pore

Drug molecules dock onto SGLT2 without touching SGLT1 mostly.

Dose-dependent occupancy of transporter population

Higher dose blocks a larger fraction of transporters.

Falling Tubular Maximum for Glucose Reabsorption

Blocked transporters shrink the kidney's glucose-reclaiming capacity.

• ~90% of SGLT2: Max blockade achieved (dose-dependent ceiling)
• Proportional to dose: Reabsorption capacity drop (linear-ish response)
• SGLT1 (~10%): Residual reabsorption route (downstream segment)
• Insulin-independent: Mechanism dependence (works despite resistance)

Tubular maximum (Tm) shifts downward with blockade

Less transporter capacity means glucose passes reabsorption unclaimed.

Independent of insulin signaling or beta-cell function

Effect persists even with insulin resistance present.

Glucosuria and Mild Osmotic Diuresis

Unreabsorbed glucose exits into urine, pulling water along.

• ~60–80 g/day: Glucose excretion (at effective dose)
• ~240–320 kcal/day: Caloric loss (via urinary glucose)
• Osmotic pull: Diuresis mechanism (mild volume/BP effect)
• First dose: Onset (sustained with therapy)

Osmotic diuresis accompanies urinary glucose loss

Glucose in urine draws extra water and sodium out.

Caloric loss contributes modestly to weight reduction

Daily sugar loss adds a small caloric deficit.

Insulin-Independent Glucose Lowering Plus Cardiorenal Protection

Kidney-driven glucose loss lowers blood sugar and protects organs.

• ~0.5–1.0%: HbA1c reduction (monotherapy or add-on)
• ~30%: HF hospitalization reduction (across major trials)
• Significantly slowed: CKD progression (independent of glucose effect)
• Insulin-independent + hemodynamic: Mechanism class (dual benefit pathway)

Glucose control achieved without relying on insulin

Glycemic benefit holds even in advanced insulin resistance.

Cardiorenal protection observed beyond glucose lowering

Trials show fewer heart failure and kidney events.